Dana-Farber Cancer Institute and Medocity Collaborate on Novel Approach to Real-time Patient-Centered Coordinated Care

by | Oct 28, 2015 | News

MORRISTOWN, NJ – Medocity Inc. and Dana-Farber Cancer Institute have launched a new research study to utilize Medocity’s patient-centered mobile solution for patients undergoing treatment for Gastrointestinal (GI) cancer including self-assessment and self-management of symptoms and side effects while patients are at home.

The unique study uses Medocity’s integrated platforms, iCancerHealth™ for patients and Medocity MD for clinicians, to connect patients in Dana-Farber’s Gastrointestinal Cancers treatment center with their clinical care team in real-time to manage medications, symptoms and side effects from treatment.

The Principal Investigator at Dana-Farber, Donna Berry, PhD, RN, stated, “We know from randomized trials that monitoring and self-care, along with communication facilitators in patients receiving cancer therapies, result in significant benefit for the patient; the iCancerHealth platform has the potential to provide exactly that type of support.”

“We are excited to have Dana-Farber as a partner for this innovative, patient-centered research study that aligns with our mission to bridge the gap between clinic and the patient’s home,” said Raj Agarwal, CEO and President of Medocity. “We believe real-time coordinated care, supporting early detection of symptoms and side effects with proactive interventions, will enhance patient care and may reduce overall healthcare costs including avoidable ER visits and hospitalizations,” added Agarwal.

Dana-Farber’s clinical care team will utilize the Medocity MD platform for virtual interaction with study participants for continuity of care and monitoring between clinical visits using system-generated alerts for symptoms and side effects. The platform uses algorithm-based management to facilitate care delivery and communicate effectively with patients in a secured environment.

The study investigators will measure the feasibility of deploying the platform to both patients and clinicians. Dana-Farber will enroll 70 cancer patients and up to ten clinicians. The study is expected to completed by early 2017.

With iCancerHealth, Medocity aims to:

  • Improve patient experiences at care by enhancing communication and transparency of patient–reported outcomes (PRO) between patients, caregivers and clinicians.
  • Enhance patient care at home by providing self-care tools and secured messaging, voice and video with the care team.
  • Facilitate peer-powered online community support for cancer patients for psychological, social, family and career related impact.

See the original Business Wire Press Release

About Dana-Farber Cancer Institute

Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard Medical School and is among the leading cancer research and care centers in the United States. It is a founding member of the Dana-Farber / Harvard Cancer Center (DF/HCC), designated a comprehensive cancer center by the National Cancer Institute. Dana-Farber is the top ranked cancer center in New England, according to U.S. News & World Report, and one of the largest recipients among independent hospitals of National Cancer Institute and National Institutes of Health grant funding.

About Medocity

Medocity, headquartered in Parsippany, New Jersey, is a recognized leader in comprehensive virtual care products and services including chronic condition management, televisits, and remote patient monitoring. Our unique, innovative technology combines multiple telehealth capabilities onto a single, integrated care coordination and management platform, along with robust clinical intelligence including rules-based algorithms, alerts and decision support tools to help drive earlier detection and proactive interventions.

The Medocity platform is specifically designed to enable and improve patient-centered care delivered outside the hospital setting, particularly for patients at home who have chronic conditions responsible for more than 80% of the nation’s annual healthcare spend. By promoting patient-clinician engagement through shared connectivity and virtual technology, we enable rich, real-time interactions between patients, clinicians, care professionals and support teams.

Our vision is to dramatically improve care at lower cost for patients when they need it the most – when they’re at home, on their own, or in between visits with their care providers. Virtually. (